Table 4

Adherence and persistence by oral anticoagulant

OverallVKADabigatranRivaroxabanApixaban
Total, n (%)36 65225 008128558554504
Zero follow-up16 (0.04)7 (0.03)1 (0.08)5 (0.09)3 (0.07)
Total <1 year of data11 373 (31.0)5307 (21.2)441 (34.3)3014 (51.5)2611 (58.0)
Primary non-adherence1800 (15.8)818 (15.4)78 (17)531 (17.6)373 (14.3)
Non-adherent3178 (27.9)1654 (31.2)94 (21.3)771 (25.6)659 (25.2)
Adherent6395 (56.2)2835 (53.4)269 (61.0)1712 (56.8)1579 (60.5)
Total ≥1 year of data25 263 (68.9)19 694 (78.8)843 (65.6)2836 (48.4)1890 (42.0)
Primary non-adherence876 (3.5)631 (3.2)66 (7.8)128 (4.5)51 (2.7)
Non-adherent, non-persistent5352 (21.2)4616 (23.4)124 (14.7)378 (13.3)234 (12.4)
Adherent, non-persistent2173 (8.6)1711 (8.7)132 (15.7)232 (8.2)98 (5.2)
Non-adherent, persistent6699 (26.5)5221 (26.5)164 (19.5)766 (27.0)548 (29.0)
Persistent, adherent10 163 (40.2)7515 (38.2)357 (42.3)1332 (47.0)959 (50.7)
  • VKA, vitamin K antagonist.